Condition: COPD · Sponsor: Uniquity One (UNI)
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
This description comes directly from the study's public registry record.
Uniquity One Clinical Trials · 484-267-2500 · ClinicalTrials@uniquity.com
Anushri Walsh · 973-983-3700 · awalsh@devprobiopharma.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| Syed Research Consultants | Sheffield, Alabama, United States | Recruiting |
| Phoenix Medical Group | Peoria, Arizona, United States | Recruiting |
| Epic Medical Research-Surprise | Sun City, Arizona, United States | Recruiting |
| Alliance for Multispecialty Research | Tempe, Arizona, United States | Recruiting |
| Novak Clinical Research | Tucson, Arizona, United States | Recruiting |
| Antelope Valley Clinical Trials | Lancaster, California, United States | Recruiting |
| Ark Clinical Research - Ballinger | Long Beach, California, United States | Recruiting |
| Downtown LA Research Center, Inc. | Los Angeles, California, United States | Recruiting |
| Newport Native MD, Inc. | Newport Beach, California, United States | Recruiting |
| OM Research | Oxnard, California, United States | Recruiting |
| Prospective Research Innovations, Inc. | Rancho Cucamonga, California, United States | Recruiting |
+ 106 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.